03.06.25 -- Which Of These 6 Outsourcing Models Best Suits Your Program?

Understanding the structural properties and impurities of biotherapeutic molecules is crucial for regulatory submissions and product development. As biotherapeutics become more complex, new analytical challenges emerge. This webinar covers advanced tools like mass spectrometry, biophysical characterization, and high throughput analytics to ensure safe, compliant medicines. Click here to learn more.

Persephoni BioPartners CEO Hilary Schultz has created a business model that may propel “externalization” to an ultimate implementation: The formation of a biotech by outsourcing the entire organization, which then outsources to advance an asset. Schultz describes Persephoni as a venture studio. Chief Editor Louis Garguilo investigates further ...

In early-phase stability programs for drug development, precise sample preparation for UHPLC testing is crucial to ensure accurate and reliable stability data.

Whether you’re trying to achieve speed and cost-effectiveness or higher yields and glycosylation capabilities, the right system can be tailored to meet the needs of each unique biologic.

Partner with a CDMO that understands the unique challenges of emerging biopharma, providing expert guidance in formulation development, manufacturing, and regulatory navigation.

Stable bulk cultures, made highly uniform using transposase-mediated technologies, may be the key to expediting clone selection for many biopharmaceutical applications.

CDMO customers consistently state that access to near real-time data is crucial to their ability to make timely, informed decisions, especially during early development.

Explore the benefits of the XS® Pichia 2.0, including speed, simple fermentation regimes, and robust, scalable processes that can be tuned according to the specific objectives of a program.

Utilize this comprehensive suite of services for the manufacture, characterization, and storage of cell banks as well as the advantages of working with an experienced partner.

An experienced contract manufacturer can help drug developers to better utilize internal resources, leverage deep industry experience, and mitigate risk across development cycles.

Leverage advanced elemental impurity testing methods to ensure the safety, compliance, and accuracy of your drug products throughout the manufacturing process.

Speed up your time to market and reduce your risk of selecting individual components that may not work well together by choosing the Ready Pack containment solution.

Discover how Lonza Biologics’ end-to-end Drug Product capabilities support the full lifecycle of biologics, seamlessly integrated with their extensive drug substance network across diverse modalities.

BD Libertas™ Wearable Injector is designed to deliver subcutaneous injections of large volume (2-5 mL or 5-10 mL) and/or high viscosity (up to 50 cP) fixed dose biologics for the non-acute setting.

It is necessary to achieve a well-designed and developed potency assay as it is the only analytical technique that can demonstrate the biological mechanism of action and the link to clinical efficacy.